News|Articles|March 3, 2026

5 Hematology Headlines You Missed in February 2026

In February 2026, rusfertide garnered priority review, ASH published new guidelines, and luspatercept mets its primary endpoint in a phase 2a trial.

In February 2026, the hematology field was introduced to new guidelines by the American Society of Hematology (ASH), the US Food and Drug Administration (FDA) provided updated news on rusfertide, and luspatercept (Reblozyl®) met both primary endpoints in a phase 2a trial.